0
0
New Delhi, Apr 13 – A recent study indicates that weekly injections of the drug tirzepatide can lead to significant and sustained weight loss for as long as three years in adults dealing with overweight or obesity who do not have diabetes.
The findings, presented at the European Congress on Obesity (ECO) in Malaga, Spain, stem from a continued analysis of the SURMOUNT-1 phase 3 clinical trial. The research, led by Dr. Luca Busetto from the University of Padova, Italy, in collaboration with the drug’s manufacturer, Eli Lilly and Company, specifically examined the long-term effectiveness of tirzepatide for weight management.
Results showed that participants maintained meaningful weight loss over the three-year period. Notably, the study observed that women and individuals without other obesity-related health complications tended to have a more effective response to the treatment.
“Our data confirm that tirzepatide can help maintain meaningful weight loss for up to three years, regardless of a person’s age, BMI, or the duration of obesity,” stated Dr. Busetto. He added that while consistent results were seen across various groups, “treatment outcomes varied, with better results seen in women and individuals without obesity-related complications.”
Tirzepatide works by mimicking two natural gut hormones, GLP-1 and GIP. These hormones play roles in regulating blood sugar levels and appetite. The drug helps by slowing down the emptying of the stomach and interacting with brain receptors involved in signaling fullness, which consequently helps reduce food intake.
Regarding safety, the extended study period did not reveal any new safety issues. The most frequently reported side effects remained gastrointestinal in nature, including nausea, diarrhea, and constipation.
The drug has received regulatory approval for weight management under specific conditions. In the United States, the FDA approved it as Zepbound in November 2023. In the European Union, it was approved as Mounjaro in June 2024. These approvals are generally for adults with obesity, or those who are overweight and also have at least one weight-related health issue such as high blood pressure, type 2 diabetes, or high cholesterol.
Researchers suggest these findings could support the development of more personalized weight loss strategies, allowing treatments to be better tailored to an individual’s specific characteristics and overall health profile.
Disclaimer: This news article is based on information presented at a medical conference and related study findings. It is for informational purposes only and should not be considered medical advice. Individuals should consult with a qualified healthcare professional before making any decisions regarding their health or treatment.
